MedTrace Logo

Immunogenicity Study of the Japanese Encephalitis Vaccine IC51

NCT00604708 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 867

Last updated 2024-03-21

Study results available
· View outcomes & findings →

Summary

The objective is to demonstrate the non-inferiority of the Japanese Encephalitis vaccine IC51 compared to JE-VAX in healthy subjects aged \> or = 18 years

Conditions

  • Japanese Encephalitis

Interventions

BIOLOGICAL

IC51

IC51 (JE-PIV), 6 mcg, i.m. injection, 2 vaccinations, days 0 and 28

BIOLOGICAL

JE-VAX

JE-VAX, 1mL s.c. injection, 3 vaccinations, days 0, 7 and 28

Sponsors & Collaborators

  • Valneva Austria GmbH

    lead INDUSTRY

Principal Investigators

  • Astrid Kaltenboeck, Ph.D. · Valneva Austria GmbH

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2006-09-30
Completion
2006-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00604708 on ClinicalTrials.gov